1083181-70-7 Usage
General Description
2-(1-Benzylpiperidin-3-yl)ethanamine, also known by the chemical formula C16H24N2, is a psychoactive compound and a derivative of piperidine. It is a powerful and selective agonist for the δ-opioid receptor, which has been shown to have potential therapeutic effects for the treatment of various medical conditions such as chronic pain and mood disorders. This chemical has also been found to have anxiolytic, antidepressant, and analgesic properties. It is considered to have a high affinity for the δ-opioid receptor and exhibits a high level of selectivity for this receptor compared to other opioid receptors. Additionally, research has shown that 2-(1-Benzylpiperidin-3-yl)ethanamine does not induce significant respiratory depression, making it a potentially safer alternative to traditional opioid medications.
Check Digit Verification of cas no
The CAS Registry Mumber 1083181-70-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,3,1,8 and 1 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1083181-70:
(9*1)+(8*0)+(7*8)+(6*3)+(5*1)+(4*8)+(3*1)+(2*7)+(1*0)=137
137 % 10 = 7
So 1083181-70-7 is a valid CAS Registry Number.
1083181-70-7Relevant articles and documents
Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors
Brazzolotto, Xavier,Gobec, Stanislav,Gro?elj, Uro?,Knez, Damijan,Malikowska-Racia, Natalia,Meden, An?e,Nachon, Florian,Sa?at, Kinga,Svete, Jurij
, (2020/09/15)
A series of tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors was designed and synthesized. Compounds were optimized in terms of potency, selectivity, and synthetic accessibility. The crystal structure of the inhibitor 18 in complex with BChE revealed the molecular basis for its low nanomolar inhibition (IC50 = 2.8 nM). The favourable in vitro results enabled a first-in-animal in vivo efficacy and safety trial, which demonstrated a positive impact on fear-motivated and spatial long-term memory retrieval without any concomitant adverse motor effects. Altogether, this research culminated in a handful of new lead compounds with promising potential for symptomatic treatment of patients with Alzheimer's disease.
